Historical record - last NADAC effective date: 3/23/2016
Product Information
VICKS NYQUIL SEVERE COLD-FLU is a brand product labeled by The Procter & Gamble Manufacturing Company, priced at $0.0235 per ML under NDC 37000081212. Its NADAC has been published 15 times since Dec 23, 2015.
VICKS NYQUIL SEVERE COLD-FLU
Acetaminophen, Dextromethorphan Hydrobromide, Doxylamine Succinate, and Phenylephrine HydrochlorideStrength
650; 20; 12.5; 10 mg/30mL; mg/30mL; mg/30mL; mg/30mL
Manufacturer
The Procter & Gamble Manufacturing CompanyNDC
37000081212
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
3/23/2016
Active Ingredients
ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; DOXYLAMINE SUCCINATE; PHENYLEPHRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
7/22/2013
Pharmacological Classes
Price Statistics
The NADAC for VICKS NYQUIL SEVERE COLD-FLU has been published 15 times since Dec 23, 2015, and over the history we have for it it has risen 73.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0235 per ML |
|---|---|
| All-time high | $0.0235 (Mar 30, 2016) |
| All-time low | $0.0135 (Dec 23, 2015) |
| Median price | $0.0135 |
| Average price | $0.0148 |
| Largest weekly change | +73.8% (Mar 23, 2016) |
| Weeks tracked | 15 |
| Tracking since | Dec 23, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+73.8%
Last surveyed Mar 30, 2016 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
The Procter & Gamble Manufacturing Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen, Dextromethorphan Hydrobromide, Doxylamine Succinate, and Phenylephrine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antihistamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VICKS NYQUIL SEVERE COLD-FLU?
The current National Average Drug Acquisition Cost (NADAC) for VICKS NYQUIL SEVERE COLD-FLU, manufactured by The Procter & Gamble Manufacturing Company, is $0.0235 per ML (NDC 37000081212), effective Mar 30, 2016.
How has the price of VICKS NYQUIL SEVERE COLD-FLU changed over time?
Over the history we have for it, the NADAC for VICKS NYQUIL SEVERE COLD-FLU has risen 73.8%. It has been tracked across 15 weekly CMS publications since Dec 23, 2015.
What are the highest and lowest recorded NADAC prices for VICKS NYQUIL SEVERE COLD-FLU?
Since Dec 23, 2015, the NADAC for VICKS NYQUIL SEVERE COLD-FLU has ranged from a low of $0.0135 (Dec 23, 2015) to a high of $0.0235 (Mar 30, 2016), with a median of $0.0135 per ML.
Are there cheaper alternatives to VICKS NYQUIL SEVERE COLD-FLU?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VICKS NYQUIL SEVERE COLD-FLU in a comparable dosage form, but none are currently priced below it.
Who manufactures VICKS NYQUIL SEVERE COLD-FLU?
VICKS NYQUIL SEVERE COLD-FLU (NDC 37000081212) is labeled by The Procter & Gamble Manufacturing Company, and CMS classifies it as a brand product.